Eric Durand

Nathan Bigaud, Vincent Cabeli, Meltem Gürel et al.

While large language models (LLMs) are rapidly advancing scientific research, they continue to struggle with core biological reasoning tasks essential for translational and biomedical discovery. To address this limitation, we created and curated eight comprehensive benchmark datasets comprising over 300,000 verifiable question-and-answer pairs, each targeting critical challenges in drug discovery including target druggability, modality suitability, and drug perturbation effects. Using this resource, we developed the OwkinZero models by post-training open-source LLMs through a Reinforcement Learning from Verifiable Rewards strategy. Our results demonstrate that specialized 8-32B OwkinZero models substantially outperform larger, state-of-the-art commercial LLMs on these biological benchmarks. Remarkably, we uncover evidence of a key aspect of generalization: specialist models trained on a single task consistently outperform their base models on previously unseen tasks. This generalization effect is further amplified in our comprehensive OwkinZero models, which were trained on a mixture of datasets and achieve even broader cross-task improvements. This study represents a significant step toward addressing the biological reasoning blind spot in current LLMs, demonstrating that targeted reinforcement learning on carefully curated data can unlock generalizable performance in specialized models, thereby accelerating AI-driven biological discovery.

Benjamin Adjadj, Pierre-Antoine Bannier, Guillaume Horent et al.

Cell detection, segmentation and classification are essential for analyzing tumor microenvironments (TME) on hematoxylin and eosin (H&E) slides. Existing methods suffer from poor performance on understudied cell types (rare or not present in public datasets) and limited cross-domain generalization. To address these shortcomings, we introduce HistoPLUS, a state-of-the-art model for cell analysis, trained on a novel curated pan-cancer dataset of 108,722 nuclei covering 13 cell types. In external validation across 4 independent cohorts, HistoPLUS outperforms current state-of-the-art models in detection quality by 5.2% and overall F1 classification score by 23.7%, while using 5x fewer parameters. Notably, HistoPLUS unlocks the study of 7 understudied cell types and brings significant improvements on 8 of 13 cell types. Moreover, we show that HistoPLUS robustly transfers to two oncology indications unseen during training. To support broader TME biomarker research, we release the model weights and inference code at https://github.com/owkin/histoplus/.

Barbara Bodinier, Gaetan Dissez, Lucile Ter-Minassian et al.

High-throughput preclinical perturbation screens, where the effects of genetic, chemical, or environmental perturbations are systematically tested on disease models, hold significant promise for machine learning-enhanced drug discovery due to their scale and causal nature. Predictive models trained on such datasets can be used to (i) infer perturbation response for previously untested disease models, and (ii) characterise the biological context that affects perturbation response. Existing predictive models suffer from limited reproducibility, generalisability and interpretability. To address these issues, we introduce a framework of Layered Ensemble of Autoencoders and Predictors (LEAP), a general and flexible ensemble strategy to aggregate predictions from multiple regressors trained using diverse gene expression representation models. LEAP consistently improves prediction performances in unscreened cell lines across modelling strategies. In particular, LEAP applied to perturbation-specific LASSO regressors (PS-LASSO) provides a favorable balance between near state-of-the-art performance and low computation time. We also propose an interpretability approach combining model distillation and stability selection to identify important biological pathways for perturbation response prediction in LEAP. Our models have the potential to accelerate the drug discovery pipeline by guiding the prioritisation of preclinical experiments and providing insights into the biological mechanisms involved in perturbation response. The code and datasets used in this work are publicly available.